These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 7843174)

  • 1. Use of teicoplanin in community medicine.
    Wilson AP; Grüneberg RN
    Eur J Clin Microbiol Infect Dis; 1994 Sep; 13(9):701-10. PubMed ID: 7843174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teicoplanin in the treatment of serious infection.
    Schaison G; Graninger W; Bouza E
    J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.
    Spencer CM; Bryson HM
    Pharmacoeconomics; 1995 Apr; 7(4):357-74. PubMed ID: 10155323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
    LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
    Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological considerations in the economic evaluation of glycopeptides].
    García-Quetglas E; Sádaba B; Honorato J
    Rev Clin Esp; 1997 Sep; 197 Suppl 2():68-73. PubMed ID: 9441326
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of serious staphylococcal infections in the outpatient setting.
    Graninger W; Presterl E; Wenisch C; Schwameis E; Breyer S; Vukovich T
    Drugs; 1997; 54 Suppl 6():21-8. PubMed ID: 9474478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O; Ferry T; Ader F; Boibieux A; Braun E; Bouaziz A; Karsenty J; Forestier E; Laurent F; Lustig S; Chidiac C; Valour F;
    BMC Infect Dis; 2016 Nov; 16(1):622. PubMed ID: 27809799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A risk-benefit assessment of teicoplanin in the treatment of infections.
    de Lalla F; Tramarin A
    Drug Saf; 1995 Nov; 13(5):317-28. PubMed ID: 8785019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
    Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues.
    Craven PC
    Hosp Formul; 1993 Jan; 28 Suppl 1():41-5. PubMed ID: 10123838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial.
    Weinberg WG
    South Med J; 1993 Aug; 86(8):891-7. PubMed ID: 8351549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative efficacy and safety of teicoplanin and vancomycin.
    Wood MJ
    J Antimicrob Chemother; 1996 Feb; 37(2):209-22. PubMed ID: 8707731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
    Nathwani D; Barlow GD; Ajdukiewicz K; Gray K; Morrison J; Clift B; France AJ; Davey P
    J Antimicrob Chemother; 2003 Feb; 51(2):391-6. PubMed ID: 12562708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of the use of teicoplanin in patients with haematological malignancies and solid tumours.
    Davies JM
    Infection; 1998; 26(6):389-95. PubMed ID: 9861566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teicoplanin vs vancomycin: cost-effectiveness comparisons.
    Rybak MJ
    Hosp Formul; 1993 Jan; 28 Suppl 1():28-32. PubMed ID: 10123835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Problems with teicoplanin in the treatment of osteoarticular infections caused by methicillin-resistant S. aureus].
    Gómez J; Climent C; Herrero F; Ruano L
    Enferm Infecc Microbiol Clin; 1992 Nov; 10(9):567-8. PubMed ID: 1489810
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.